The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes
Open accessAbstract
BACKGROUND: Long-term trends in excess risk of death and cardiovascular outcomes have not been extensively studied in persons with type 1 diabetes or type 2 diabetes. METHODS: We included patients registered in the Swedish National Diabetes Register from 1998 through 2012 and followed them through 2014. Trends in deaths and cardiovascular events were estimated with Cox regression and standardized incidence rates. For each patient, controls who were matched for age, sex, and county were randomly selected from the general population. RESULTS: Among patients with type 1 diabetes, absolute changes during the study period in the incidence rates of sentinel outcomes per 10,000 person-years were as follows: death from any cause, -31.4 (95% confidence interval [CI], -56.1 to -6.7); death from cardiovascular disease, -26.0 (95% CI, -42.6 to -9.4); death from coronary heart disease, -21.7 (95% CI, -37.1 to -6.4); and hospitalization for cardiovascular disease, -45.7 (95% CI, -71.4 to -20.1). Absolute changes per 10,000 person-years among patients with type 2 diabetes were as follows: death from any cause, -69.6 (95% CI, -95.9 to -43.2); death from cardiovascular disease, -110.0 (95% CI, -128.9 to -91.1); death from coronary heart disease, -91.9 (95% CI, -108.9 to -75.0); and hospitalization for cardiovascular disease, -203.6 (95% CI, -230.9 to -176.3). Patients with type 1 diabetes had roughly 40% greater reduction in cardiovascular outcomes than controls, and patients with type 2 diabetes had roughly 20% greater reduction than controls. Reductions in fatal outcomes were similar in patients with type 1 diabetes and controls, whereas patients with type 2 diabetes had smaller reductions in fatal outcomes than controls. CONCLUSIONS: In Sweden from 1998 through 2014, mortality and the incidence of cardiovascular outcomes declined substantially among persons with diabetes, although fatal outcomes declined less among those with type 2 diabetes than among controls. (Funded by the Swedish Association of Local Authorities and Regions and others.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Atherosclerotic cardiovascular disease (ASCVD) broadly refers to a history of acute coronary syndrome, myocardial infarction (MI), stable or unstable angina or coronary or other arterial revascularization, stroke, transient ischemic attack, or peripheral artery disease (PAD) including aortic aneurysm and is the leading cause of morbidity and mortality in people with diabetes (1).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [1]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“ASCVD broadly refers to a history of acute coronary syndrome, myocardial infarction (MI), stable or unstable angina or coronary or other arterial revascularization, stroke, or peripheral artery disease (PAD) including aortic aneurysm and is the leading cause of morbidity and mortality in people with diabetes (1).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [1]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Under the current paradigm of comprehensive risk factor modification, cardiovascular morbidity and mortality have notably decreased in people with both type 1 and type 2 diabetes (1).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [1]
The cited source says what the claim attributes to it.
In the citing paper
“Under the current paradigm of comprehensive risk factor modification, cardiovascular morbidity and mortality have notably decreased in people with both type 1 and type 2 diabetes (1).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [1]
In the citing paper
“T2DM is common among patients with ASCVD or at the highest risk of CVD.The converse is also true: ASCVD is common in patients with T2DM.148”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [148]
In the citing paper
“Diabetes is a well-established risk factor for ischaemic heart disease (IHD), and CAD accounts for 40-80% of deaths in patients with T2DM.148,359,381”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [148]
In the citing paper
“These results were consistent across subgroups including those with and without diabetes or CKD.”
From SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the National Kidney Foundation (2021) · cites this paper as [50]
In the citing paper
“The primary outcome of worsening HF or CVD death was significantly reduced, 16.3% versus 21.2% for dapagliflozin compared with placebo (HR, 0.74; 95% CI, 0.65–0.85).”
From SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the National Kidney Foundation (2021) · cites this paper as [50]
In the citing paper
“Patients with T2DM are at high risk for ASCVD and HF compared with nondiabetic individuals (50,53).”
From SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the National Kidney Foundation (2021) · cites this paper as [50]
In the citing paper
“DAPA-HF was the first clinical trial of an SGLT2 inhibitor to assess HF events as the primary outcome and to include participants with and without diabetes (50).”
From SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the National Kidney Foundation (2021) · cites this paper as [50]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
C-Reactive Protein, Interleukin 6, and Risk of Developing Type 2 Diabetes Mellitus
Pradhan, A. D. (2001) · JAMA · doi:10.1001/jama.286.3.327 · Cited by 4,433
Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes
Gæde, P., Vedel, P., Larsen, N., Jensen, G. V. H., Parving, H.-H., & Pedersen, O. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021778 · Cited by 4,378
IDF Diabetes Atlas: Global estimates of the prevalence of diabetes for 2011 and 2030
Whiting, D. R., Guariguata, L., Weil, C., & Shaw, J. E. (2011) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2011.10.029 · Cited by 4,018
Colhoun, H. M., Betteridge, D. J., Durrington, P. N., Hitman, G. A., W Neil, H. A., Livingstone, S. J., Thomason, M. J., Mackness, M. I., Charlton-Menys, V., & Fuller, J. H. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16895-5 · Cited by 3,755
Effect of a multifactorial intervention on mortality in type 2 diabetes
Gæde, P., Lund-Andersen, H., Parving, H.-H., & Pedersen, O. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706245 · Cited by 3,465
Flagged first, then by citations
Cited by
Sorted by citations
Items 701–800 of 1,000
Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes
Al-Bazz, D. Y., & Wilding, J. P. H. (2020) · Future Cardiology · doi:10.2217/fca-2019-0065 · Cited by 8
Patient-perceived service needs and health care utilization in people with type 2 diabetes
Ni, Y., Liu, S., Li, J., Li, S., & Dong, T. (2020) · Medicine · doi:10.1097/md.0000000000020322 · Cited by 8
Taylor, G., Shaw, A., Smith, K., Capper, T. E., Scragg, J. H., Cronin, M., Bashir, A., Flatt, A. J., Campbell, M. D., Stevenson, E., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-93886-2 · Cited by 8
Ji-ji, X., Li, L., Huang, S., Song, H., Gao, J., Ni, H., Lin, H., Wang, S., Li, M., Wang, T., et al. (2022) · Journal of Diabetes · doi:10.1111/1753-0407.13253 · Cited by 8
Jermendy, G., Kiss, Z., Rokszin, G., Abonyi‐Tóth, Z., Wittmann, I., & Kempler, P. (2019) · Diabetologia Hungarica · doi:10.24121/dh.2019.15 · Cited by 8
Pioglitazone and cardiovascular risk in T2DM patients: is it good for all?
Abdul‐Ghani, M. A., Jayyous, A., Asaad, N., Helmy, S., & Suwaidi, J. M. S. A. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.03.19 · Cited by 8
Yokoyama, H., Araki, S., Kawai, K., Yamazaki, K., Tomonaga, O., Maeda, H., Ohtaki, M., Obata, H., Sone, H., Kabata, D., et al. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110674 · Cited by 7
Zhang, L., Reshetnyak, E., Ringel, J. B., Pinheiro, L. C., Carson, A. P., Cummings, D. M., Durant, R. W., Malla, G., & Safford, M. M. (2024) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2023.0380 · Cited by 7
Non-Invasive and Accurate Blood Glucose Detection Based on an Equivalent Bioimpedance Spectrum
Gong, Q., Xu, C., Yuan, H., Shi, X., Li, W., Li, X., & Fang, C. (2025) · Applied Sciences · doi:10.3390/app15031266 · Cited by 8
Khalafi, M., Dinizadeh, F., Rosenkranz, S. K., Symonds, M. E., & Fatolahi, S. (2025) · Healthcare · doi:10.3390/healthcare13030246 · Cited by 7
Cardioprotection During Myocardial Infarction in Diabetic Cardiomyopathy
Alcover, S., López-Bernal, S., Ramos-Regalado, L., Muñoz‐García, N., Gallinat, A., Suades, R., Badimón, L., & Vilahur, G. (2025) · Diabetes · doi:10.2337/db24-0510 · Cited by 7
Nilsson, K., Andersson, E., Persson, S., Karlsdotter, K., Skogsberg, J., Gustavsson, S., JENDLE, J. H., & Carlsson, K. S. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14921 · Cited by 7
Role of purinergic receptors in cardiac sympathetic nerve injury in diabetes mellitus.
Hu, Q.-X., & Li, G.-L. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109406 · Cited by 5
Mattsson, K., Pihlsgård, M., Enhörning, S., & Timpka, S. (2024) · Hypertension · doi:10.1161/hypertensionaha.123.22081 · Cited by 7
Immune checkpoint modulators in early clinical development for the treatment of type 1 diabetes
Maddaloni, E., Amendolara, R., Balena, A., Latino, A., Sessa, R. L., & Buzzetti, R. (2024) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2024.2326036 · Cited by 7
Chepulis, L. M., Rodrigues, M. A., Gan, H., Keenan, R., Kenealy, T. W., Murphy, R., Karu, L. T., Scott‐Jones, J., Clark, P., Moffitt, A., et al. (2025) · BMC Health Services Research · doi:10.1186/s12913-025-12601-3 · Cited by 7
Zhang, X., Peng, N., Zhang, X., Zhu, Z., Yan, M., Wu, Y., Ling, J., Li, C., Gu, W., Zhang, J., et al. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01712-w · Cited by 9
Mortality in adults with and without diabetes: is the gap widening?
Wang, Z., Zhang, H., & Liu, M. (2017) · Clinical Epidemiology · doi:10.2147/clep.s148101 · Cited by 7
Quantifying the Risk Continuum for Cardiovascular Death in Adults with Type 2 Diabetes
Williams, B. A., Blankenship, J. C., Voyce, S. J., Cordova, J. M., Gandhi, P., & Shetty, S. S. (2021) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2021.01.009 · Cited by 8
Blin, P., Darmon, P., Henry, P., Guiard, E., Bernard, M., Dureau‐Pournin, C., Maizi, H., Thomas‐Delecourt, F., Lassalle, R., Droz‐Perroteau, C., et al. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01416-1 · Cited by 7
Zatońska, K., Basiak-Rasała, A., Połtyn–Zaradna, K., Różańska, D., Karczewski, M., Wołyniec, M., & Szuba, A. (2021) · Vascular Health and Risk Management · doi:10.2147/vhrm.s321700 · Cited by 7
Saving time by replacing the standardised two-hour oral glucose tolerance test with a one-hour test
Ferrannini, G., Bacquer, D. D., Gyberg, V., Backer, G. D., Kotseva, K., Mellbin, L., Risebrink, R., Tuomilehto, J. O., Wood, D., & Rydén, L. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.109156 · Cited by 7
Jensen, E. S., Olesen, K. K. W., Gyldenkerne, C., Thrane, P. G., Jensen, L. O., Raungaard, B., Poulsen, P. L., Thomsen, R. W., & Mæng, M. (2021) · BMC Cardiovascular Disorders · doi:10.1186/s12872-021-02312-y · Cited by 7
Mazin, I., Chernomordik, F., Fefer, P., Matetzky, S., & Beigel, R. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11071904 · Cited by 8
Role of Ertugliflozin in the Management of Diabetes Mellitus
Totade, M., & Gaidhane, S. (2022) · Cureus · doi:10.7759/cureus.31404 · Cited by 7
Brieler, J. A., Salas, J., Garrett, E. K., & Scherrer, J. F. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.12.066 · Cited by 8
Liu, S., Eckstein, J., Lam, A. P., & Cheema, A. N. (2023) · Current Vascular Pharmacology · doi:10.2174/1570161121666230131120544 · Cited by 7
Goh, Y. A., Lan, N. S. R., Linn, K., Wood, C., Gupta, A., Yeap, B. B., & Fegan, P. G. (2023) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2023.108557 · Cited by 8
How Effective are Gliflozins as DPP-4 Inhibitors? A Computational Study
Saini, K., Khan, Y., & Sharma, S. (2023) · Theoretical Foundations of Chemical Engineering · doi:10.1134/s0040579523030168 · Cited by 7
Bielinskyi, M. V., Seredyuk, N. M., Fedorov, S. V., Herashchenko, A. S., & Volynskyi, D. A. (2023) · EMERGENCY MEDICINE · doi:10.22141/2224-0586.19.5.2023.1609 · Cited by 7
Serés‐Noriega, T., Viñals, C., Perea, V., Mesa, A., Boswell, L., Mariaca, K., Blanco, J., Vinagre, I., Pané, A., Milad, C., et al. (2024) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3783 · Cited by 7
Kwak, S. H., Hernandez-Cancela, R. B., DICORPO, D. A., Condon, D. E., Merino, J., Wu, P., Brody, J. A., Yao, J., Guo, X., Ahmadizar, F., et al. (2024) · Diabetes Care · doi:10.2337/dc23-2274 · Cited by 7
Jernberg, T., Lindholm, D. P., Hasvold, L. P., Svennblad, B., Bodegård, J., Andersson, K., Thuresson, M., Erlinge, D., & Janzon, M. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-027199 · Cited by 7
Nyström, T., James, S. K., Lindahl, B., Östlund, O., Erlinge, D., Herlitz, J. D., Ömerovic, E., Mellbin, L., Alfredsson, J., Fröbert, O., et al. (2019) · Diabetes Care · doi:10.2337/dc19-0590 · Cited by 7
Pomero, F., Dentali, F., Mumoli, N., Salomone, P., Tangianu, F., Desideri, G., & Mastroiacovo, D. (2019) · Acta Diabetologica · doi:10.1007/s00592-019-01426-2 · Cited by 7
Niakan, M. H., Dehghankhalili, M., Pourdavood, A. H., Vahidi, A., Nazemi, S., Piranviseh, A., & Hasanvand, K. (2020) · The Foot · doi:10.1016/j.foot.2020.101688 · Cited by 7
Mohammedi, K., Préaubert, N., Cariou, T., Rigalleau, V., Foussard, N., Piazza, L., Bairras-Martin, C., Couffinhal, T., Bezin, J., & Bénard, A. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01253-2 · Cited by 7
Nøkleby, K., Berg, T. J., Mdala, I., Buhl, E. S., Claudi, T., Cooper, J. G., Løvaas, K. F., Sandberg, S., & Jenum, A. K. (2021) · Diabetic Medicine · doi:10.1111/dme.14586 · Cited by 7
Li, W., Lv, X., Liu, J., Zeng, J., Ye, M., Li, C., Fan, R., Lin, H., Huang, H., & Yao, F. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.677990 · Cited by 7
Zoppini, G., Bergamini, C., Trombetta, M., Sabbagh, L., Dauriz, M., Mantovani, A., Targher, G., Fossà, I., Rinaldi, E., & Bonora, E. (2019) · Journal of Endocrinological Investigation · doi:10.1007/s40618-019-01032-7 · Cited by 7
Ohmura, H., Mita, T., Matsuoka, J., Nojiri, S., Nishizaki, Y., Watada, H., Daida, H., & SPIRITS-J Study Investigators (2019) · Diabetes Therapy · doi:10.1007/s13300-019-0626-2 · Cited by 7
Tofte, N., Theilade, S., Winther, S. A., Birkelund, S., Goetze, J. P., Hansen, T. W., & Rossing, P. R. (2020) · Diabetes Care · doi:10.2337/dc20-2107 · Cited by 7
Heavier but Healthier — Diabetes and Smoking Cessation
Schroeder, S. A. (2018) · New England Journal of Medicine · doi:10.1056/nejme1809004 · Cited by 7
Masuda, H., Ishiyama, D., Yamada, M., Iwashima, F., Kimura, Y., Otobe, Y., Tani, N., Suzuki, M., & Nakajima, H. (2021) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s307070 · Cited by 6
Khodabandehloo, P., Fakembe, P., Senga, J., Shulman, R., Lipscombe, L. L., Witteman, H. O., Banerjee, A., Presseau, J., Nakhla, M., Dogba, M. J., et al. (2025) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.16426 · Cited by 6
“18,19 22 Inequitable use of diabetes technologies contributes at least in part to worse diabetes outcomes for socially disadvantaged groups with T1D (e.g., racial or ethnic minority or lower socioeconomic status [SES]).”
Zhang, Z., Wang, C., Zhao, L. Y., Wang, Z., Zhou, X., Yang, W., & Meng, X. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16293 · Cited by 7
Bekier, M., Szkutnik-Fiedler, D., Urjasz, H., & Uruska, A. A. (2025) · Scientific Reports · doi:10.1038/s41598-025-12605-3 · Cited by 6
Brown, J. E., Newson, L., Umeh, K. F., Lotto, R. R., & Jones, I. D. (2025) · Psychology and Health · doi:10.1080/08870446.2025.2546411 · Cited by 6
Schneidewind, J., von Sengbusch, S., Schmidt, D., & Lange, K. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112477 · Cited by 6
Nassif, M. E., & Kosiborod, M. (2019) · The American Journal of Medicine · doi:10.1016/j.amjmed.2019.08.003 · Cited by 6
Neubauer‐Geryk, J., Wielicka, M., Kozera, G., Myśliwiec, M., Zorena, K., & Bieniaszewski, L. (2020) · Physiological Reports · doi:10.14814/phy2.14518 · Cited by 6
Okechukwu, U. C., Ugwu, T. E., Abonyi, M. C., Chukwubuzo, O. T., Nnaji, T. O., & Ume, N. M. (2023) · Annals of Clinical and Biomedical Research · doi:10.4081/acbr.2023.243 · Cited by 6
Wang, X., Ma, H., Li, X., Liang, Z., Fonseca, V. A., & Qi, L. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15443 · Cited by 6
Vlacho, B., Fernández‐Camins, B., Canudas-Ventura, A., Garrocho, A. R., Molló, À., Cos, X., Antentas, M., Mauricio, D., & Franch‐Nadal, J. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13061544 · Cited by 6
Tatulashvili, S., Dreves, B., Meyer, L., Cosson, E., & Joubert, M. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111592 · Cited by 8
Estrategias para la prevención y tratamiento no farmacológico de la diabetes. Modelos de atención
López, M. A. B. (2024) · Atención Primaria · doi:10.1016/j.aprim.2024.102947 · Cited by 7
Xu, C. Y., Zhang, S., An, J., Jia, C., Zhang, X., Li, P., Guan, Y., Yan, Y., Zhao, Z., Liu, Y., et al. (2024) · Environmental Pollution · doi:10.1016/j.envpol.2024.125008 · Cited by 6
Relationship between liver and cardiometabolic health in type 1 diabetes
Tas, E., Vu, B.-M. K., Mendizábal, B., Libman, I. M., & Muzumdar, R. H. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1505430 · Cited by 6
Loktionova, M. V., Mohammadian, M., Choopani, R., Kheiri, S., & Mohammadian-Hafshejani, A. (2024) · PLoS ONE · doi:10.1371/journal.pone.0314565 · Cited by 6
RetractedSaedi, S., Tan, Y., Watson, S. E., Sparks, J. D., Wintergerst, K. A., & Cai, L. (2025) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00673.2024 · Cited by 6
Registration and Real-Life Studies on Automated Insulin Delivery Systems
Aktürk, H. K., Brown, S. A., Beck, R. W., Sherr, J. L., Bergenstal, R. M., Kovatchev, B. P., Vigersky, R. A., Breton, M. D., Hovorka, R., Klonoff, D. C., et al. (2025) · Journal of Diabetes Science and Technology · doi:10.1177/19322968251334993 · Cited by 6
Registration and Real-Life Studies on Automated Insulin Delivery Systems
Aktürk, H. K., Brown, S. A., Beck, R. W., Sherr, J. L., Bergenstal, R. M., Kovatchev, B. P., Vigersky, R. A., Breton, M. D., Hovorka, R., Klonoff, D. C., et al. (2025) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2025.0130 · Cited by 6
Song, D. K., Sung, Y., Hong, Y. S., Kim, M. H., & Lee, H. (2025) · Scientific Reports · doi:10.1038/s41598-025-01768-8 · Cited by 6
CVOTs: What did the endocrinologist learn?
Valensi, P. E., & Prévost, G. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.107947 · Cited by 6
Lyu, F., Cai, X., Lin, C., Hong, T., Zhang, X., Lu, J., Guo, X., Wang, Z., Xing, H., Zong, G., et al. (2021) · Chinese Medical Journal · doi:10.1097/cm9.0000000000001741 · Cited by 6
Maio, A., Maiorino, M. I., Longo, M., Scappaticcio, L., Pernice, V., Cirillo, P., Caruso, P., Paglionico, V. A., Bellastella, G., & Esposito, K. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac316 · Cited by 6
Antidiabetic Drug Prescription Pattern in Hospitalized Older Patients with Diabetes
Ardoino, I., Mandelli, S., Baviera, M., Rossio, R., Nobili, A., Mannucci, P. M., Franchi, C., & Investigator, O. B. O. R. (2023) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph20032607 · Cited by 6
Temporal trends in cardiovascular outcomes and costs among patients with type 2 diabetes
Williams, B. A., RAJPURA, J. R., Paprocki, Y., Kumar, N., Voyce, S. J., Brady, J. P., & Chang, A. R. (2023) · American Heart Journal · doi:10.1016/j.ahj.2023.07.012 · Cited by 7
Avgerinos, I., Kakotrichi, P., Karagiannis, T., Bekiari, E., & Τσάπας, Α. (2024) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2024.2324918 · Cited by 6
piRNAs as emerging biomarkers and physiological regulatory molecules in cardiovascular disease
Liu, Z., & Zhao, X. P. (2024) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2024.149906 · Cited by 6
Fang, F., Wang, N., Yan, S., Wang, L., Lu, Y., Li, J., Li, H., Pham, G., Li, C., Leng, S. X., et al. (2019) · Primary care diabetes · doi:10.1016/j.pcd.2019.01.004 · Cited by 6
Padovani, C., Arruda, R. M. D. C., & Sampaio, L. M. M. (2019) · Brazilian Journal of Cardiovascular Surgery · doi:10.21470/1678-9741-2019-0027 · Cited by 6
Lan, N. S. R., Burns, K. A., Bell, D. A., & Watts, G. F. (2020) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000594 · Cited by 6
Carral, F., Tomé, M., Alba, J. J. F., Zaldivar, A. P., Expósito, C., Jiménez, A. I., García, C., & Ayala, C. (2020) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2020.07.009 · Cited by 6
Read, S. H., Rosella, L. C., Berger, H. M., Feig, D. S., Fleming, K., Kaul, P., Ray, J. G., Shah, B. R., & Lipscombe, L. L. (2021) · Diagnostic and Prognostic Research · doi:10.1186/s41512-021-00095-6 · Cited by 6
Forster, R., Strandberg, R. B., Tibballs, K. L. B., Nøkleby, K., Berg, T. J., Iversen, T., Hagen, T. P., Richardsen, K. R., Cooper, J. G., Sandberg, S., et al. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-054840 · Cited by 6
Registry-based randomised clinical trials: a remedy for evidence-based diabetes care?
Eriksson, J. W., Eliasson, B., Bennet, L., & Sundström, J. (2022) · Diabetologia · doi:10.1007/s00125-022-05762-x · Cited by 7
Self-citationMorieri, M. L., Pipino, C., & Doria, A. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12091402 · Cited by 6
Ke, C., Lipscombe, L. L., Weisman, A., Zhou, L., Austin, P. C., Shah, B. R., & Booth, G. L. (2023) · Diabetes Care · doi:10.2337/dc23-0952 · Cited by 6
Patrono, C. (2017) · Cardiovascular Research · doi:10.1093/cvr/cvx209 · Cited by 6
Two clinical cases of adjunctive use of a SGLT-2 inhibitor in type 1 diabetes
Siegmund, T., Ampudia‐Blasco, F. J., & Schnell, O. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108131 · Cited by 6
ENTPD3-specific CAR regulatory T cells for local immune control in T1DPreprint
Pieper, T., Riët, T., Saetzler, V., Bergerhoff, K. F., McGovern, J. L., Delsing, L., Atkinson, M. A., Lodie, T. A., Jermutus, L., Noyan, F., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.11.12.622951 · Cited by 6
Popovic, D. S., Patoulias, D., Koufakis, T., Karakasis, P., & Παπάνας, Ν. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01657-9 · Cited by 6
Chan, J. C. N., Deerochanawong, C., Khunti, K., Hassanein, M. M., & Mohan, V. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113173 · Cited by 6
Yang, J., Zhang, J. I. A. N., Huang, R., Meng, K., Liang, J.-J., Lin, J., Wang, J., Wang, Y., Gao, Y., Qu, Y., et al. (2026) · Redox Biology · doi:10.1016/j.redox.2026.104228 · Cited by 5
Wang, J., Wu, Y., Ou, H., Yang, Y., Hsu, C., & Hwu, C. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.984137 · Cited by 5
Social and Structural Determinants of Cardiovascular Complications of Diabetes
MENSAH, P. A., VALDEZ, K., Gyawali, A., & Snell‐Bergeon, J. K. (2024) · Current Diabetes Reports · doi:10.1007/s11892-024-01541-7 · Cited by 5
Are cardiac rehabilitation pathways influenced by diabetes: A cohort study
Gadager, B. B., Tang, L. H., Doherty, P., Svendsen, M. L., Sibilitz, K. L., Harrison, A. S., & Maribo, T. (2024) · International Journal of Cardiology · doi:10.1016/j.ijcard.2024.132275 · Cited by 7
Giuffrida, F. M. A., Rai, S. K., Tang, Y., Mendonça, C., Frodsham, S. G., Shah, H., Pezzolesi, M. G., Sun, Q., & Doria, A. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02442-5 · Cited by 5
Liang, Y., Zhou, R., Jin, C., Liang, J., Wang, X., Fan, W., Wu, X., & Zou, M. (2024) · Nutrients · doi:10.3390/nu17010113 · Cited by 5
Li, J., Jiang, L., Fu, Y., Zhang, K., Tan, X. W., Wang, N., Li, X., Lu, Y., & Wang, B. (2025) · The American Journal of Medicine · doi:10.1016/j.amjmed.2025.05.001 · Cited by 5
Therapeutic potential of anti-thymocyte globulin in type 1 diabetes: A systematic review
Mittal, R., McKenna, K., Lemos, J. R. N., Juneja, S., Mittal, M., & Hirani, K. (2025) · PLoS ONE · doi:10.1371/journal.pone.0323642 · Cited by 5
Rizzi, A., Polimeno, T., Leo, M. L., Moriconi, A., Policriti, M. A., Tartaglione, L., Merola, A., Tropea, A., Apa, R., & Pitocco, D. (2025) · Endocrine Practice · doi:10.1016/j.eprac.2025.06.020 · Cited by 5
Paliares, I. C., Dualib, P. M., Aroucha, P. M. T., Torres, L. S. N., de Sá, J. R., & Dib, S. A. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112386 · Cited by 6
Zhang, S., Xu, C. Y., Jia, C., An, J., Zhang, X., Guan, Y., Yan, Y., Zhao, Z., Liu, Y., Jing, T., et al. (2025) · Eco-Environment & Health · doi:10.1016/j.eehl.2025.100185 · Cited by 5
Bauduceau, B., Bordier, L., Bringer, J., Chabrier, G., Charbonnel, B. H., Cosson, E., Darmon, P., Detournay, B., Fontaine, P., Gourdy, P., et al. (2019) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(19)30056-2 · Cited by 7
Williams, B. A., Brady, J. P., Voyce, S. J., Kumar, N., Paprocki, Y., & RAJPURA, J. R. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14686 · Cited by 5
Implementation of Cardiometabolic Centers and Training Programs
Taha, M. B., Rao, N., Vaduganathan, M., Cainzos‐Achirica, M., Nasir, K., & Patel, K. V. (2022) · Current Diabetes Reports · doi:10.1007/s11892-022-01459-y · Cited by 5
Camoin, M., Velho, G., Saulnier, P., Potier, L., Abouleka, Y., Carpentier, C., Dubois, S. G., Larroumet, A., Rigalleau, V., Gand, E., et al. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01487-8 · Cited by 6
Koziolova, N. A., Polyanskaya, Е. А., & Миронова, С. (2022) · South Russian Journal of Therapeutic Practice · doi:10.21886/2712-8156-2022-3-4-7-24 · Cited by 5
Metadata
- Authors
- Rawshani, A., Rawshani, A., Franzén, S., Eliasson, B., Svensson, A.-M., Miftaraj, M., McGuire, D. K., Sattar, N., Rosengren, A., & Gudbjörnsdottir, S.
- Affiliations
- University of Glasgow (GB)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-04-13
- Volume
- 376
- Issue
- 15
- Pages
- 1407-1418
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2606281213
- Cited by
- 1,389
- References
- 37
- Citations by year
- 2026: 100 · 2025: 144 · 2024: 163 · 2023: 149 · 2022: 184 · 2021: 176 · 2020: 196 · 2019: 140 · 2018: 95 · 2017: 39
- FWCI
- 101.54
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- type 1 diabetes, type 2 diabetes, cardiovascular disease, mortality, coronary artery disease, cardiovascular hospitalization, Sweden, diabetes registry, standardized incidence rate
- MeSH terms
- Adolescent, Adult, Aged, Cardiovascular Diseases, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Female, Hospitalization, Humans, Male, Middle Aged, Mortality, Registries, Risk Factors, Sweden, Incidence, Proportional Hazards Models, Age of Onset
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
